ArticleBMC immunology2026
Cellular immune response during BK polyomavirus infection in living donor kidney transplant recipients.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBK polyomavirus (BKPyV) is a significant cause of graft impairment and loss following kidney transplantation. Early prediction of which patients are at risk of BKPyV replication and BKPyV-associated nephropathy (BKPyVAN) would be beneficial, preferably prior to transplantation. From an immunological perspective, determinants of susceptibility to BKPyV reactivation remain incompletely understood. The aim of this study was to evaluate the prognostic value of lymphocyte subset counts, CD4/8 T cell ratio, and changes in CD4 + T cell counts over time. Additionally, the concept of Immune Risk Profile (IRP), defined as CD4/CD8 ratio combined with cytomegalovirus (CMV) seropositivity, was evaluated as an immunological tool to estimate the risk of developing a clinically significant BKPyV replication.
methodsThis study was part of a single-centre prospective cohort including adult kidney transplant recipients between 2016 and 2018 at Uppsala University Hospital, Sweden. All recipients were routinely screened for BKPyV DNA in plasma and urine every 3 months for up to 18 months after transplantation. Immune cell phenotyping was performed using flow cytometry on blood samples collected from both living donors and recipients at the time of transplantation, as well as from recipients during follow-up.
resultsIn 21 of the 68 recipients (31%), BKPyV replication was detected in blood and/or urine; 11 (16%) had DNAemia. Recipients who later developed BKPyV replication had lower CD4/CD8 ratios before transplantation compared to those who remained BKPyV replication negative. Seventeen recipients (25%) met the criteria for IRP-positivity, of whom 9 (53%) developed BKPyV replication, indicating a higher risk compared to the IRP-negative recipients (OR 3.66, 95% CI 1.08-10.79; p = 0.034). The total T cell counts, as well as CD4 + and CD8 + T cell counts, increased 1-2 months post-transplantation compared with pre-transplant levels in both recipients who developed BKPyV replication and those who did not.
conclusionsRecipients with a low CD4/CD8 ratio and IRP-positive status were more likely to develop subsequent BKPyV replication, supporting a role for T cell imbalance in susceptibility to viral reactivation. However, the observed differences were modest and substantial overlap between the groups limits the clinical utility of these markers for individualizing BKPyV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.